Delayed
Japan Exchange
12:59:26 2024-07-18 am EDT
5-day change
1st Jan Change
446
JPY
-0.67%
+4.69%
-15.85%
Linical : (Delayed)FY 2022 Financial Results Briefing(2,410kb)
*Please note that this translation is to be used solely as reference.
In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.
FY 2022 Financial Results Briefing
Monday, May 23, 2022
Kazuhiro Hatano
President and CEO
Linical Co.,Ltd.
TSE Prime 2183
1. Business Orveview
P. 2 ~ 4
2. Financial Results for FY ended March 2022 P. 5 ~ 15
3. Forecasts of FY ending March 2023
P. 16 ~ 18
4. Management Strategy
P. 19 ~ 28
Global CRO from Japan
Beijing
Canada
Korea
Illinois
Germany
Tokyo
Spain
Czech
Shang
San Diego
New York
Republic
Osaka
Poland
France
India
hai
(Linical Headquarters)
Florida
Hungary
Romania
UK Netherlands
Taiwan
Mexico
Italy
Philippines
Singapore
Brazil
Indonesia
South Africa
Australia
Chile
Argentina
Red: Headquarters Orange: Branch Pink: Subsidiary Blue: Subsidiary Green: CRA Employment ash: Under consideration as base
Linical aims to be a global CRO originating in Japan and contributes to new drug development as a drug
development professional
We currently operate in 18 countries and regions, and can provide services in more than 20 countries and
regions worldwide
3
Trends in Sales and Operating Income since Establishment
Sales and Operating Income since Establishment (Billions of Yen)
Net Sales
Operating Profit
Net Sales
100
November 2014
European CRO
Acquisition of
Nuvisan
Operating
April 2018
115
Profit
50
U.S. CRO
Accelovance
Acquisition
113
109
10340
91
83
January 2014
77
30
March 2013
October 2008
Korea CRO
First Section
P-Pro Acquisition
50
Mothers Listed
of the Tokyo
20
Stock
49
COVID-19
June 2005
Exchange
36
37
Establishment
25
31
10
24
20
1
13
0
6
0
(Fiscal Year) 2006/3 2007/3 2008/3 2009/3 2010/3 2011/3 2012/3 2013/3 2014/3 2015/3 2016/3 2017/3 2018/3 2019/3 2020/3 2021/3 2022/3
We achieved our highest ever sales while the impacts of COVID-19 remained in each region
Operating profit has also recovered to pre-COVID-19 levels
4
This is an excerpt of the original content. To continue reading it, access the original document here .
Attachments
Original Link
Original Document
Permalink
Disclaimer
Linical Co. Ltd. published this content on 28 June 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 15 July 2022 15:33:05 UTC .
Linical's Fiscal-Year Net Profit More than Halves on Restructuring Costs
Jun. 10
MT
Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on June 12, 2024; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2025
May. 15
CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2025
May. 15
CI
Linical Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Apr. 12
CI
Linical Cuts Revenue, Earnings Forecast on Lower-Than-Expected Sales, Extraordinary Losses
Feb. 21
MT
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024
Feb. 14
CI
Linical Seeks Listing on Standard Market Following Revised Tokyo Stock Exchange Rules
23-09-26
MT
Linical Co., Ltd. Provides Dividend Forecast for the Year Ending March 31, 2024
23-08-14
CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024
23-08-14
CI
Linical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-15
CI
Linical Co., Ltd. Provides Forecast of Consolidated Financial Result for the Year Ending March 31, 2024
23-05-15
CI
Linical Co., Ltd. Provides Year Ending Dividend Forecast for the Year Ending March 31, 2024
23-05-15
CI
Linical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2023
23-05-15
CI
Linical Co., Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2023
23-02-14
CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
23-02-14
CI
Linical Co., Ltd. Provides Earnings Guidance for the Year Ending March 2023
22-12-27
CI
Linical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2023
22-12-27
CI
Science 37 Holdings, Linical Americas to Deploy Decentralized Clinical Trial Services
22-11-17
MT
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
22-11-14
CI
Linical Co., Ltd.(TSE:2183) dropped from S&P Global BMI Index
22-09-19
CI
Linical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
22-08-12
CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
22-08-12
CI
Linical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
22-05-16
CI
Linical Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 9, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
22-05-16
CI
Linical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022
22-02-14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.
More about the company
1st Jan change
Capi.
-15.85% 64.77M +24.74% 47.54B -0.47% 41.96B +43.96% 41.55B +25.40% 30.36B +17.96% 27.61B -4.47% 28.7B +50.73% 14.7B +42.56% 13.51B +1.46% 12.34B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1